Our ambition : to share
our expertise internationally

LXO Group is a dynamic pharmaceutical company that has been built with the patient in mind. We aim to achieve our ambition through growth via international expansion, acquisitions and leveraging our expertise in life cycle management.

OUR STORY

LXO Group, a success story in France... and abroad

2015

Company creation as Laboratoire X.O. Acquisition of two assets: Mynocine and Atépadène.

2016

Acquisition of six assets: Solubacter, Inofer, Cutisan, Mantadix, Esomeprazole and Ketoprofe

2017

Acquisition of eight assets: Nebcine, Exacor, Logirene, theralene, Prexidine, Trolovol, Zumalgic, Karaya

2018

Acquisition of three assets: Loxen, Vitamine D, Physiomycine

2019

Aqcuisition of two assets: Gynopatch, Bonasol

2020

Majority buyout by Novalpina Capital. Aquisition of two assets: Sodium alginate, Prexicare

2021

Expansion in Europe with the acquisition of Rydene, Cardene, and Vasonase

2022

Majority buyout by Stanley Capital. Acquisition of one company Noden Pharma and two assets: Tekturna, Goprelto.

2023

Laboratoire X.O becomes LXO Group. Acquisition of one asset: Nimotop

LXO GROUP

Our strengths

Finished pharmaceutical products: 95% manufactured in Europe
Oversight and security of API production
Developing high performing teams and top talent
A strong financial partner that shares our ambitions
Distribution in more than 80 countries

Check out our global footprint

OUR VALUES

The values that inspire us

EXCELLENCE

Alongside the ethical values specific to our industry, we are committed to putting the best of our expertise at the service of patients, healthcare professionals and our partners.

AGILITY

We know how to adapt in a complex, constantly changing world, where the ability to innovate and reinvent ourselves is key. Our dynamic, dedicated teams are committed to what we do every day.

PASSION

We develop and distribute medicines first and foremost to help healthcare professionals and their patients. We support our employees on a daily basis and share our mission with them, creating a sense of belonging within the Group.

OUR BOARD

Governance serving our growth

In 2022, we entered a new phase of our growth with the support of Stanley Capital. This European fund is committed to a dynamic strategy of Global acquisitions, with substantial additional financing already agreed.